Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.
India’s largest biopharmaceutical company, Biocon Ltd., has introduced its biosimilar Avastin (bevacizumab) on the domestic market, backed by a strategy that seeks to move beyond price competition.
While Biocon’s Krabeva appears to be priced along similar lines as the biosimilar bevacizumab from competitor Intas Pharmaceuticals Ltd.,...